Penumbra Net Change in Short-term Investments 2014-2025 | PEN
Penumbra annual/quarterly net change in short-term investments history and growth rate from 2014 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Penumbra net change in short-term investments for the quarter ending March 31, 2025 was $0.013B, a 41.36% decline year-over-year.
- Penumbra net change in short-term investments for the twelve months ending March 31, 2025 was $0.275B, a 3250.94% increase year-over-year.
- Penumbra annual net change in short-term investments for 2024 was $0.098B, a 15532.96% increase from 2023.
- Penumbra annual net change in short-term investments for 2023 was $0.001B, a 99.16% decline from 2022.
- Penumbra annual net change in short-term investments for 2022 was $0.074B, a 2510.15% decline from 2021.
| Penumbra Annual Net Change in Short-term Investments (Millions of US $) |
|
|---|---|
| 2024 | $98 |
| 2023 | $1 |
| 2022 | $74 |
| 2021 | $-3 |
| 2020 | $-101 |
| 2019 | $18 |
| 2018 | $30 |
| 2017 | $-53 |
| 2016 | $14 |
| 2015 | $-80 |
| 2014 | $-33 |
| 2013 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $11.301B | $1.195B |
| Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. | |||